Generic Name and Formulations:
Rosiglitazone (as maleate), glimepiride; 4mg/1mg, 4mg/2mg, 4mg/4mg, 8mg/2mg, 8mg/4mg; tabs.
Various generic manufacturers
Indications for Rosiglitazone/Glimepiride:
Adjunct to diet and exercise for type 2 diabetes when dual therapy is appropriate.
≥18yrs: Take once daily with first meal of the day. Drug-naive: 4mg/1mg. Previously on thiazolidinedione monotherapy: initially 4mg/1mg or 4mg/2mg; if inadequate response after 1–2 weeks, may increase glimepiride component in ≤2mg increments at 1–2 week intervals. Previously on sulfonylurea monotherapy: initially 4mg/1mg or 4mg/2mg; if inadequate response, may increase rosiglitazone component after 8–12 weeks. Previously on rosiglitazone and glimepiride: switch on a mg/mg basis. Max 8mg rosiglitazone/4mg glimepiride per day. Elderly, debilitated, malnourished, renal, hepatic or adrenal insufficiency: initially 4mg/1mg once daily; titrate carefully to avoid hypoglycemia.
<18yrs: not established.
NYHA Class III or IV heart failure. Sulfonamide allergy.
Not for treating type 1 diabetes or diabetic ketoacidosis. Symptomatic HF or acute coronary syndromes: not recommended; discontinue if occurs. CHF: NYHA Class I or II: increased risk of cardiovascular events (monitor). Edema. May increase plasma volume (monitor for heart failure); discontinue if cardiac status deteriorates. Monitor for weight gain/fluid retention. Risk of cardiovascular mortality. Hepatic disease. Do not start therapy in active liver disease or if ALT >2.5xULN. Monitor transaminases at baseline, then periodically. If ALT is mildly elevated (≤2.5xULN), follow-up and monitor closely; discontinue if ALT >3xULN or jaundice occurs. Not for use in patients with history of troglitazone-associated jaundice. Risk of fractures (esp. women). G6PD deficiency. Stress, uncompensated strenuous exercise, deficient caloric intake, or alcohol intoxication: increased risk of hypoglycemia. Resumption of premenopausal ovulation in anovulatory patients may occur (may result in unintended pregnancy). Reevaluate if menstrual dysfunction occurs. Elderly. Labor & delivery. Pregnancy (Cat.C) (consider using insulin instead), nursing mothers: not recommended.
Concomitant insulin or nitrates: not recommended. Potentiated by CYP2C8 inhibitors (eg, gemfibrozil). Antagonized by CYP2C8 inducers (eg, rifampin). May be potentiated by alcohol, NSAIDs, highly protein bound drugs, oral miconazole, salicylates, sulfonamides, chloramphenicol, warfarin, probenecid, MAOIs, β-blockers. May be antagonized by diuretics, corticosteroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, isoniazid, estrogens, oral contraceptives. May be affected by CYP2C9 substrates (eg, rifampin, fluconazole). Separate colesevelam dosing by ≥4 hours. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.
Thiazolidinedione + sulfonylurea.
Headache, hypoglycemia, nasopharyngitis, upper respiratory tract infection, injury, edema, weight gain, anemia, macular edema (possible), hypersensitivity reactions (eg, angioedema, Stevens-Johnson syndrome); discontinue if occurs. See full labeling re: risk of myocardial ischemic events.
Formerly known under the brand name Avandaryl.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies